US · Healthcare · Diagnostics & Research
EPS came in at 3.12 against a street estimate of 2.81 — a beat of 11.0%.
Analysts rate Quest Diagnostics Incorporated a buy (9 buy, 9 hold, 0 sell out of 18) with an average price target of $246.73.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.34% |
| Vanguard Capital Management, LLC | 6.50% |
| T. Rowe Price Associates, Inc. | 5.73% |
| Vanguard Portfolio Management, LLC | 5.53% |
| State Street Corp | 4.89% |
| Boston Partners Global Investors, Inc | 4.31% |
| JPMorgan Chase & Co | 3.50% |
| Geode Capital Management, LLC | 2.81% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 QUEST DIAGNOSTICS INC (DGX) - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $3,043 million (vs. $2,761 million in Q2 2025) — up 10.2% • S | 2026-07-23 |
| Results announced · Q3 2026 QUEST DIAGNOSTICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $3.04 billion, up 10.2% year-over-year; organic revenue growth 10.0% | 2026-07-23 |
| Shareholder vote results · Q2 2026 QUEST DIAGNOSTICS INC - DOCUMENT SUMMARY HEADLINE NUMBERS • Annual Meeting held May 20, 2026 • 11 directors elected to board for terms expiring at 2 | 2026-05-21 |
| Material agreement · Q2 2026 QUEST DIAGNOSTICS INCORPORATED — FORM 8-K SUMMARY HEADLINE NUMBERS • Quest Diagnostics issued $500,000,000 in senior notes on May 6, 2026 • Interest | 2026-05-08 |
| Company announcement · Q2 2026 QUEST DIAGNOSTICS INCORPORATED – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issuing $500 million aggregate principal amount of 5.000% senior notes | 2026-05-01 |
| Quarterly report · Q1 2026 QUEST DIAGNOSTICS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenues Q1 2026: $2,895 million (vs. $2,652 million in Q1 2025, +9.2% increase | 2026-04-22 |
| Proxy statement · Q2 2026 QUEST DIAGNOSTICS INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • James E. Davis (CEO, Chairman, President) total 2025 compensation: Not stated in p | 2026-04-06 |
| Annual report FY2025 QUEST DIAGNOSTICS INC - SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net Revenues 2025: $11.0 billion • Market Capitalization (as of June 30, 202 | 2026-02-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.86 / share ex-date Oct 6, 2026 · pay Oct 21, 2026 | 2026-10-06 |
| Dividend | $0.86 / share ex-date Jul 8, 2026 · pay Jul 22, 2026 | 2026-07-08 |
| Dividend | $0.86 / share ex-date Apr 6, 2026 · pay Apr 20, 2026 | 2026-04-06 |
| Dividend | $0.80 / share ex-date Jan 13, 2026 · pay Jan 28, 2026 | 2026-01-13 |
| Dividend | $0.80 / share ex-date Oct 3, 2025 · pay Oct 20, 2025 | 2025-10-03 |
| Announcement | Date |
|---|---|
| Board authorizes $1B stock repurchase; quarterly dividend raised 7.5% Quest Diagnostics announced its Q4 2025 and full-year 2025 financial results on February 10, 2026. Along with the earnings announcement, the company's Board of Directors made two shareholder | 2026-02-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quest Diagnostics Incorporated — free to start.
Google PlayApp StoreData updated 2026-09-18.